RVMD Q4 2022 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+62.1% YoY

Gross Profit

$15M100.0% margin

Operating Income

-$62M-402.5% margin

Net Income

-$57M-368.6% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+356.8%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$65M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$812M

Total Liabilities

$127M

Stockholders' Equity

$685M

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$9M	+62.1%
Gross Profit	$15M	$9M	+62.1%
Operating Income	-$62M	-$53M	-16.6%
Net Income	-$57M	-$53M	-7.3%

Revenue Segments

Collaboration Revenue Member

$15M100%